Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients

Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients

Background/Objectives: Our previous retrospective single-center cohort study found, at 3-year follow-up, a trend toward low tacrolimus trough levels and an increased risk of de novo donor-specific anti-HLA antibodies (DSAs) and of antibody-mediated rejection (ABMR) in CYP3A5-expressing patients. Det...

Full description

Saved in:
Bibliographic Details
Main Authors: Kristina Schönfelder, Birte Möhlendick, Ute Eisenberger, Andreas Kribben, Winfried Siffert, Falko M. Heinemann, Anja Gäckler, Benjamin Wilde, Justa Friebus-Kardash
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Diagnostics
Subjects:
<i>CYP3A5</i> polymorphism
tacrolimus dosage
tacrolimus trough levels
anti-HLA antibodies
DSAs
renal transplant rejection
Online Access:https://www.mdpi.com/2075-4418/14/19/2202
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items